DuoDote® Auto-Injector
(atropine and pralidoxime chloride injection), for intramuscular use
You Are Now Leaving the MeridianMeds.com Website
Links to other sites are provided as a convenience to the viewer.
Pfizer accepts no responsibility for the content of linked sites.
Use DuoDote in the presence of life-threatening poisoning by organophosphorus nerve agents or insecticides.5
Learn more about DuoDote and the different kinds of nerve agent poisonings it treats in our presentation and videos.5
Indication:
DuoDote, a combination of atropine, a cholinergic muscarinic antagonist, and pralidoxime chloride, a cholinesterase reactivator, is indicated for the treatment of poisoning by organophosphorus nerve agents as well as organophosphorus insecticides in adults and pediatric patients weighing more than 41 kg (90 pounds).
Please see full Prescribing Information.
| Key Product Specifications6: | |
|---|---|
| NSN | 6505-01-581-1327 |
| NDC | 11704-620-01 |
| Delivers | 2.1 mg atropine in 0.7 mL and 600 mg pralidoxime chloride in 2 mL sequentially through a single needle using the two-chambered BinaJect® drug delivery system. |
| Length of Unit | 145 mm |
| Diameter of Unit | 19 mm |
| Needle Gauge | 23 |
| Needle Length | 21 mm |
| Administration Type | Intramuscular injection |
| Packaged | 1 auto-injector per box with instructions; package insert |
| Packaging for Shipping | 30 units per shipper box (286 mm x 213 mm x 210 mm), weighing 2.3 kg |
| Storage | Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) [See USP Controlled Room Temperature]. Keep from freezing. Protect from light. |
| Prescription Required | Yes |
DuoDote Mechanism of Action
How to Administer DuoDote
Adverse Event or Product Quality Complaints
If you wish to report an adverse event or product quality complaint, please call 1-800-438-1985.
For medical questions concerning Meridian products, to report an adverse event, or to speak to a member of Pfizer US Medical Information, please call 1-800-438-1985.
You are encouraged to report side effects of prescription drugs to the FDA.
Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
Medical Information
If you have a medical question concerning Meridian products, please call 1-800-438-1985.
US HCPs can visit www.pfizermedinfo.com.
DuoDote® Auto-Injector (atropine and pralidoxime chloride injection), for intramuscular use
There are no contraindications to the use of DuoDote.
Cardiovascular risks include tachycardia, palpitations, premature ventricular contractions, flutter, fibrillation, asystole, and myocardial infarction. Other cardiovascular adverse reactions have also been reported. Use caution in patients with known CV disease or conduction problems.
Heat injury may occur. Atropine may inhibit sweating and lead to hyperthermia. Avoid excessive exercising and heat exposure.
Acute glaucoma may be precipitated in susceptible individuals, and therefore DuoDote should be administered with caution in patients at risk for acute glaucoma.
Administer with caution in patients with bladder outflow obstruction as urinary retention may occur.
DuoDote should be administered with caution in patients with partial pyloric stenosis because of the risk of complete pyloric obstruction.
Atropine may cause inspiration of bronchial secretions and formation of dangerous viscid plugs and may exacerbate chronic lung disease. Monitor respiratory status.
Common adverse reactions of atropine include dryness of the mouth, blurred vision, dry eyes, photophobia, confusion, headache, and dizziness, among others. The common adverse reactions of pralidoxime chloride include changes in vision, dizziness, headache, drowsiness, nausea, tachycardia, increased blood pressure, muscular weakness, dry mouth, emesis, rash, dry skin, hyperventilation, decreased renal function, excitement, manic behavior, and transient elevation of liver enzymes and creatine phosphokinase.
Muscle tightness and pain may occur at the injection site.
Patients who have received succinylcholine and mivacurium may exhibit an accelerated reversal of the neuromuscular blocking effects when treated with DuoDote. Monitor neuromuscular effects with concomitant administration.
Safety and effectiveness of DuoDote in pediatric patients weighing less than or equal to 41 kg (90 pounds) have not been established.
Geriatric patients may be more susceptible to the effects of atropine.
Pralidoxime chloride can cause decreased renal function. Patients with severe renal impairment may require less frequent doses after the initial dose.
Patients with severe hepatic impairment may require less frequent doses after the initial dose.
Indication:
DuoDote, a combination of atropine, a cholinergic muscarinic antagonist, and pralidoxime chloride, a cholinesterase reactivator, is indicated for the treatment of poisoning by organophosphorus nerve agents as well as organophosphorus insecticides in adults and pediatric patients weighing more than 41 kg (90 pounds).
Please see full Prescribing Information.